Co-Diagnostics, Inc. CODX

Just listening to Dr. Oz on fox might as well stick your finger in your ass ??

Need to watch and Listen https://youtu.be/aiVqcIyMyR0

Co-Diagnostics Reports Surge in Demand for Coronavirus Tests
The company's shares have soared though it has offered few specifics about the financial impact its COVID-19 products are having.

Jim Crumly
Jim Crumly
(TMFSpeyside)
Mar 5, 2020 at 3:41PM
Author Bio
Shares of molecular diagnostics company Co-Diagnostics (NASDAQ:CODX) jumped 24% Thursday after the company reported a surge in demand for its tests for COVID-19. The wave of orders came following an announcement by the U.S. Food and Drug Administration last weekend that opened the door for labs to use the diagnostic tests they've developed before those tests get formal approval from the agency.

The change in FDA policy allows laboratories to use tests after in-house validation, and Co-Diagnostics said that it's receiving requests from U.S. clinical laboratories for reagents in preparation for patient testing. CEO Dwight Egan says his company is now manufacturing and shipping coronavirus products to countries on four continents, and it plans to triple its total manufacturing capacity for this test by bringing its facility in India into the effort.

Rising graph with paper airplane flying into the clouds.
IMAGE SOURCE: GETTY IMAGES.

Co-Diagnostics stock has been on a wild ride recently as investors have scrambled to buy into companies that have opportunities to profit from fighting the COVID-19 epidemic. Shares of the company soared almost five-fold in the last two weeks and are up by more than 1,400% in 2020, making it one of the biggest winners from the outbreak.

However, the Utah-based company has been rather tight-lipped about actual financial results related to its coronavirus products, and it continues to take advantage of the rising stock price by issuing new shares for direct placement with its investors. Co-Diagnostics raised $4.2 million in a direct offering of common stock this week, after raising $10.2 million on Feb. 13 and $5 million on Jan. 28.

We need some news

https://youtu.be/aiVqcIyMyR0

Co-Diagnostics, Inc. Reports Additional Demand for Coronavirus Test Shipments
Mar 5, 2020
“We are already manufacturing and shipping coronavirus products to countries on 4 continents ...., specifically in connection to this global health crisis.
“The Company continues to advance towards emergency use clearance for use as an in vitro diagnostic by the FDA as well as by the CDSCO in India.”

http://codiagnostics.com/co-diagnostics-reports-additional-demand-for-coronavirus-test/

https://www.abc4.com/news/health/coronavirus/utah-company-now-selling-coronavirus-test-in-us/

https://youtu.be/aiVqcIyMyR0

Salt Lake City, Utah – March 5, 2020 – Co-Diagnostics, Inc. (Nasdaq:CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that both domestic and international demand has surged for its novel coronavirus detection kits in recent weeks leading to increased product shipments, following the Food and Drug Administration’s (FDA) change in policy on February 29, and an ever-larger number of patients testing positive for the disease worldwide.
International interest has grown for Co-Diagnostics’ CE-IVD Logix Smart™ COVID-19 Test Kit, and numerous requests have been received from US clinical laboratories for the Company’s reagents to be used according to the FDA’s new policy allowing those labs to begin testing patients for COVID-19 after in-house validation, while awaiting FDA Emergency Use Authorization.
Co-Diagnostics CEO Dwight Egan commented “We are already manufacturing and shipping coronavirus products to countries on 4 continents along with additional demand we are experiencing pursuant to the policy change. Recent customer purchases have also included diagnostic equipment to facilitate the availability of molecular diagnostics world-wide, specifically in connection to this global health crisis.
“The Company continues to advance towards emergency use clearance for use as an in vitro diagnostic by the FDA as well as by the CDSCO in India. Our facility in that country stands to more than triple our manufacturing capacity for this test, especially important to meet potential demand in the eastern hemisphere. The additional revenues we are experiencing along with our solid balance sheet and debt-free status have all facilitated our efforts to support the global response to coronavirus.”